Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $5.85 -7.87%
Revenue Growth %: -7.0%
Financial Fact:
Earnings per diluted share: -0.02
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: -7.0%
Financial Fact:
Earnings per diluted share: -0.02
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.00, $0.01 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $205.7 million versus the consensus estimate of $204.97 million.
GUIDANCE:
Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of $0.01. Myriad Genetics sees FY2025 revenue of $818-828 million, versus the consensus of $822.4 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Waystar Holding Corp. (WAY) Reports Q3 EPS of $0.44
- Offerpad Solutions Inc. (OPAD) Misses Q3 EPS by 72c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
